Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-06-10T03:03:19.262Z Has data issue: false hasContentIssue false
  • English
  • Français

Synthesis, powder diffraction pattern, crystal structure determination of the pharmaceutical co-crystal of levetiracetam and 3,5-dinitrosalicylic acid

Published online by Cambridge University Press:  16 October 2023

Lingling Shi Open the ORCID record for Lingling Shi [Opens in a new window] ,
Zhengguo Chen ,
Hany Kafafy ,
Zhaoxia Zhang ,
Guocheng Zhu ,
Juming Yao  and
Guoqing Zhang
Lingling Shi
Affiliation:
School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
Zhengguo Chen
Affiliation:
School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
Hany Kafafy
Affiliation:
Dyeing, Printing and Auxiliaries Department, Textile Research Division, National Research Center, 33 El-Buhoth St, Dokki, Cairo 12311, Egypt
Zhaoxia Zhang
Affiliation:
School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
Guocheng Zhu
Affiliation:
School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
Juming Yao
Affiliation:
School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
Guoqing Zhang*
Affiliation:
School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
*
a)Author to whom correspondence should be addressed. Electronic mail: zgq@zstu.edu.cn
Get access Rights & Permissions [Opens in a new window]

Abstract

(S)-α-Ethyl-2-oxo-1-pyrrolidineacetamide (trade name levetiracetam), a derivative of piracetam, is used clinically as an add-on treatment for partial-onset seizures. In this study, we report the solid-state structure of a new drug co-crystal produced from levetiracetam and 3,5-dinitrosalicylic acid through cooling crystallization. This compound was further characterized by infrared spectroscopy, powder X-ray diffraction, and single-crystal X-ray diffraction. The new co-crystals show a 1:1 stoichiometry and crystallize in the monoclinic system, space group P21, with cell parameters: a = 9.7709(3) Å, b = 6.2202(2) Å, c = 14.7280(4) Å, α = 90°, β = 96.0340(10)°, γ = 90°, V = 890.16(5) Å3, and Z = 2. It is identified that hydrogen bonds are the main interactions between levetiracetam and 3,5-dinitrosalicylic acid, and the contribution of each hydrogen bond in maintaining the stability of the crystal structure was also quantified using Hirshfeld surface analysis.

Keywords

co-crystallevetiracetam3,5-dinitrosalicylic acidcrystal structure
Type
New Diffraction Data
Information
Powder Diffraction , Volume 38 , Issue 4 , December 2023 , pp. 244 - 252
Check for updates
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of International Centre for Diffraction Data

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Bolla, G., and Nangia, A.. 2016. “Pharmaceutical Cocrystals: Walking the Talk.” Chemical Communications 52 (54): 8342–60.CrossRefGoogle Scholar
Clausen, H. F., Chevallier, M. S., Spackman, M. A., and Iversen, B. B.. 2010. “Three New Co-Crystals of Hydroquinone: Crystal Structures and Hirshfeld Surface Analysis of Intermolecular Interactions.” New Journal of Chemistry 34 (2): 193–99.CrossRefGoogle Scholar
D'Ascenzo, L., and Auffinger, P.. 2015. “A Comprehensive Classification and Nomenclature of Carboxyl–Carboxyl (ate) Supramolecular Motifs and Related Catemers: Implications for Biomolecular Systems.” Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials 71 (2): 164–75.CrossRefGoogle ScholarPubMed
Dassault Systèmes. 2021. Materials Studio. V. 2021. BIOVIA. Windows.Google Scholar
Duggirala, N. K., Frericks Schmidt, H. L., Lei, Z., Zaworotko, M. J., Krzyzaniak, J. F., and Arora, K. K.. 2018. “Solid-State Characterization and Relative Formation Enthalpies to Evaluate Stability of Cocrystals of an Antidiabetic Drug.” Molecular Pharmaceutics 15 (5): 1901–08.CrossRefGoogle ScholarPubMed
El-Gizawy, S. A., Osman, M. A., Arafa, M. F., and El Maghraby, G. M.. 2015. “Aerosil as a Novel Co-Crystal Co-Former for Improving the Dissolution Rate of Hydrochlorothiazide.” International Journal of Pharmaceutics 478 (2): 773–78.CrossRefGoogle ScholarPubMed
Emami, S., Siahi-Shadbad, M., Adibkia, K., and Barzegar-Jalali, M.. 2018. “Recent Advances in Improving Oral Drug Bioavailability by Cocrystals.” Bioimpacts 8 (4): 305–20.CrossRefGoogle ScholarPubMed
Ervasti, T., Aaltonen, J., and Ketolainen, J.. 2015. “Theophylline–Nicotinamide Cocrystal Formation in Physical Mixture During Storage.” International Journal of Pharmaceutics 486 (1–2): 121–30.CrossRefGoogle ScholarPubMed
Friscic, T., and Jones, W.. 2009. “Recent Advances in Understanding the Mechanism of Cocrystal Formation via Grinding.” Crystal Growth and Design 9 (3): 1621–37.CrossRefGoogle Scholar
Kang, Y., Gu, J., and Hu, X.. 2017. “Syntheses, Structure Characterization and Dissolution of Two Novel Cocrystals of Febuxostat.” Journal of Molecular Structure 1130: 480–86.CrossRefGoogle Scholar
Lin, S. Y. 2017. “Simultaneous Screening and Detection of Pharmaceutical Co-Crystals by the One-Step DSC–FTIR Microspectroscopic Technique.” Drug Discovery Today 22 (4): 718–28.CrossRefGoogle ScholarPubMed
Newman, A. W., and Byrn, S. R.. 2003. “Solid-State Analysis of the Active Pharmaceutical Ingredient in Drug Products.” Drug Discovery Today 8 (19): 898–905.CrossRefGoogle ScholarPubMed
Nikpour, M., Mirzaei, M., Chen, Y. G., Kaju, A. A., and Bakavoli, M.. 2009. “Contribution of Intermolecular Interactions to Constructing Supramolecular Architecture: Synthesis, Structure and Hirshfeld Surface Analysis of a New Hybrid of Polyoxomolybdate and ((1H-Tetrazole-5-yl) Methyl) Morpholine.” Inorganic Chemistry Communications 12 (9): 879–82.CrossRefGoogle Scholar
Pandey, N. K., Sehal, H. R., Garg, V., Gaur, T., Kumar, B., Singh, S. K., Gulati, M., Gowthamarajan, K., Bawa, P., Rajesh, S. Y., Sharma, P., and Narang, R.. 2017. “Stable Co-Crystals of Glipizide with Enhanced Dissolution Profiles: Preparation and Characterization.” Aaps PharmSciTech 18: 2454–65.CrossRefGoogle ScholarPubMed
Ranjan, S., Devarapalli, R., Kundu, S., Vangala, V. R., Ghosh, A., and Reddy, C. M.. 2017. “Three New Hydrochlorothiazide Cocrystals: Structural Analyses and Solubility Studies.” Journal of Molecular Structure 1133: 405–10.CrossRefGoogle Scholar
Seth, S. K., Saha, N. C., Ghosh, S., and Kar, T.. 2011a. “Structural Elucidation and Electronic Properties of Two Pyrazole Derivatives: A Combined X-Ray, Hirshfeld Surface Analyses and Quantum Mechanical Study.” Chemical Physics Letters 506 (4–6): 309–14.CrossRefGoogle Scholar
Seth, S. K., Maity, G. C., and Kar, T.. 2011b. “Structural Elucidation, Hirshfeld Surface Analysis and Quantum Mechanical Study of Para-Nitro Benzylidene Methyl Arjunolate.” Journal of Molecular Structure 1000 (1–3): 120–26.CrossRefGoogle Scholar
Soman, R., Sujatha, S., and Arunkumar, C.. 2014. “Quantitative Crystal Structure Analysis of Fluorinated Porphyrins.” Journal of Fluorine Chemistry 163: 16–22.CrossRefGoogle Scholar
Song, L., Shemchuk, O., Robeyns, K., Braga, D., Grepioni, F., and Leyssens, T.. 2019. “Ionic Cocrystals of Etiracetam and Levetiracetam: The Importance of Chirality for Ionic Cocrystals.” Crystal Growth & Design 19 (4): 2446–54.CrossRefGoogle Scholar
Sopyan, I., Fudholi, A., Muchtaridi, M., and Sari, I. P.. 2017. “Simvastatin-Nicotinamide Co-Crystal: Design, Preparation and Preliminary Characterization.” Tropical Journal of Pharmaceutical Research 16 (2): 297–303.CrossRefGoogle Scholar
Spackman, M. A., and Jayatilaka, D.. 2009. “Hirshfeld Surface Analysis.” CrystEngComm 11 (1): 19–32.CrossRefGoogle Scholar
Spackman, M. A., and McKinnon, J. J.. 2002. “Fingerprinting Intermolecular Interactions in Molecular Crystals.” CrystEngComm 4 (66): 378–92.CrossRefGoogle Scholar
Spackman, P. R., Turner, M. J., McKinnon, J. J., Wolff, S. K., Grimwood, D. J., Jayatilaka, D., and Spackman, M. A.. 2021. “Crystalexplorer: A Program for Hirshfeld Surface Analysis, Visualization and Quantitative Analysis of Molecular Crystals.” Journal of Applied Crystallography 54 (3): 1006–11.CrossRefGoogle ScholarPubMed
Weijenberg, A., Brouwer, O. F., and Callenbach, P. M.. 2015. “Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review.” CNS Drugs 29: 371–82.CrossRefGoogle ScholarPubMed
Xu, Y., Jiang, L., and Mei, X.. 2014. “Supramolecular Structures and Physicochemical Properties of Norfloxacin Salts.” Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials 70 (4): 750–60.CrossRefGoogle ScholarPubMed
Yamashita, H., and Sun, C. C.. 2018. “Improving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Conformer.” Pharmaceutical Research 35: 1–7.CrossRefGoogle Scholar
Yoshimura, M., Miyake, M., Kawato, T., Bando, M., Toda, M., Kato, Y., Fukami, T., and Ozeki, T.. 2017. “Impact of the Dissolution Profile of the Cilostazol Cocrystal with Supersaturation on the Oral Bioavailability.” Crystal Growth & Design 17 (2): 550–57.CrossRefGoogle Scholar
Zhang, Y. Q., Li, J., Hu, Y., Tian, Y., and Gao, C. H.. 2010. “The Antiepileptic Drug Levetiracetam.” Chinese Journal of Neuroimmunology and Neurology 17 (2): 145–47.Google Scholar
Supplementary material: File

Shi et al. supplementary material

Shi et al. supplementary material
Download Shi et al. supplementary material(File)
File 44.7 KB